Cartesian Therapeutics, Inc.
RNAC
$8.63
-$0.08-0.86%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.78M | 2.80M | 1.09M | 1.03M | 34.17M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.78M | 2.80M | 1.09M | 1.03M | 34.17M |
| Cost of Revenue | 62.82M | 58.03M | 54.65M | 52.25M | 50.04M |
| Gross Profit | -61.05M | -55.24M | -53.56M | -51.22M | -15.87M |
| SG&A Expenses | 30.27M | 31.47M | 30.36M | 29.20M | 28.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 93.09M | 89.50M | 85.01M | 81.45M | 79.03M |
| Operating Income | -91.32M | -86.71M | -83.92M | -80.43M | -44.86M |
| Income Before Tax | -160.97M | -139.50M | -47.69M | -35.97M | -38.02M |
| Income Tax Expenses | -9.19M | -9.19M | 287.00K | 287.00K | 287.00K |
| Earnings from Continuing Operations | -151.77 | -130.30 | -47.98 | -36.26 | -38.31 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -151.77M | -130.30M | -47.98M | -36.26M | -38.31M |
| EBIT | -91.32M | -86.71M | -83.92M | -80.43M | -44.86M |
| EBITDA | -88.90M | -83.75M | -81.08M | -77.91M | -42.74M |
| EPS Basic | -5.89 | -5.11 | -1.96 | -1.70 | -1.64 |
| Normalized Basic EPS | -1.99 | -1.84 | -1.79 | -1.59 | -0.70 |
| EPS Diluted | -5.90 | -5.13 | -1.97 | -1.71 | -1.67 |
| Normalized Diluted EPS | -1.99 | -1.83 | -1.78 | -1.59 | -0.73 |
| Average Basic Shares Outstanding | 104.84M | 103.89M | 103.31M | 98.78M | 89.52M |
| Average Diluted Shares Outstanding | 105.31M | 104.36M | 103.78M | 99.24M | 90.59M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |